Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 5/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19267577 | 0.91 | SMN1; SMN2 (0.38) | SMN1; SMN2POLBALDH1A1CA2TYR | |
| SCHEMBL13550107 | 0.87 | RAPGEF4 (0.40) | SMN1; SMN2POLBALDH1A1CA2TYR | |
| SCHEMBL21892211 | 0.85 | ALDH1A1 (0.33) | SMN1; SMN2POLBALDH1A1CA2TYR | |
| SCHEMBL19267572 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2POLBALDH1A1CA2TYR | |
| SCHEMBL15187675 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBALDH1A1CA2TYR | |
| SCHEMBL18272233 | 0.80 | SMN1; SMN2 (0.40) | SMN1; SMN2POLBALDH1A1CA2TYR | |
| SCHEMBL91657 | 0.80 | SMN1; SMN2 (0.40) | SMN1; SMN2POLBALDH1A1CA2TYR | |
| SCHEMBL26712936 | 0.79 | SMN1; SMN2 (0.41) | SMN1; SMN2POLBALDH1A1CA2TYR | |
| SCHEMBL26712772 | 0.79 | SMN1; SMN2 (0.41) | SMN1; SMN2POLBALDH1A1CA2TYR | |
| SCHEMBL25613962 | 0.78 | AR (0.32) | POLBALDH1A1ARTSHRPGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6495540-B2 | HEXAHYDROAZEPINE-2-ONE DERIVATIVE AS BETA-AMYLOID INHIBITOR | BRISTOL - MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | claimed |
| US-20020010172-A1 | Lactams as inhibitors of A-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-24 | — | — | US | claimed |
| US-20230363195-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-09 | — | — | US | disclosed |
| US-20230345751-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-10-26 | — | — | US | disclosed |
| US-20230329022-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230329024-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-10-12 | — | — | US | disclosed |
| WO-2023163001-A1 | COMPOSITION, ORGANIC ELECTROLUMINESCENT ELEMENT AND METHOD FOR PRODUCING SAME, DISPLAY DEVICE, AND LIGHTING DEVICE | 三菱ケミカル株式会社 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022263497-A1 | ORGANIC ELECTRONIC DEVICES COMPRISING BIS(((Z)-3-(4-CYANO-3,5-BIS(TRIFLUOROMETHYL)PHENYL)-4-OXOPENT-2-EN-2-YL)OXY)COPPER(II) OR THE CORRESPONDING ALUMINIUM(III) OR IRON(III) COMPLEXES OR SIMILAR COMPLEXES | NOVALED GMBH (DE) | 2022-12-22 | — | — | WO | disclosed |
| US-20200235304-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-07-23 | — | — | US | disclosed |
| US-20200231596-A1 | MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE | CANGET BIOTEKPHARMA | 2020-07-23 | — | — | US | disclosed |
| WO-2019078620-A1 | NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME | 주식회사 엘지화학 | 2019-04-25 | — | — | WO | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| WO-2013058613-A2 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | 한국생명공학연구원 (KR) | 2013-04-25 | — | — | WO | disclosed |
| US-6495540-B2 | HEXAHYDROAZEPINE-2-ONE DERIVATIVE AS BETA-AMYLOID INHIBITOR | BRISTOL - MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-20020010172-A1 | Lactams as inhibitors of A-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231596-A1 | MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE | TP53, BRCA1, MET | SMN1; SMN2 499/4885POLB 1855/4885ALDH1A1 4214/4885 |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | TMPRSS2, TMPRSS4, PRSS2 | SMN1; SMN2 3022/4885POLB 4679/4885ALDH1A1 740/4885 |
| US-20020010172-A1 | Lactams as inhibitors of A-beta protein production | BACE1, APP, APH1A | SMN1; SMN2 548/4885POLB 1879/4885ALDH1A1 3399/4885 |
| US-20200235304-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | C1S, CBR3, CCNL2 | SMN1; SMN2 3242/4885POLB 2205/4885ALDH1A1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.